About this trial

To determine whether a strategy of adding venovenous ECMO to mechanical ventilation, as compared to mechanical ventilation alone, increases the number of intensive care free days at day 60, in patients with moderate to severe acute hypoxic respiratory failure.

Eligibility criteria

Qualifiers

Patients ≥18 to 65 years old

Acute hypoxemic respiratory failure characterised by new or worsening respiratory symptoms developing within 2 weeks prior to the onset of need for oxygen or respiratory support

Mechanical ventilation of <7 days

Moderate to severe respiratory failure, as demonstrated by two P:F ratios <150mmHg at least 6 hours apart. Arterial Blood Gases (ABG) with P:F ratio > 150mmHg are permitted between the two trial inclusion ABGs.

Disqualifiers

The patient will be extubated today or tomorrow (i.e. will not remain intubated and ventilated the day after tomorrow)

Cardiogenic cause of respiratory failure

Chronic hypercapnic respiratory failure defined as PaCO2 > 60 mmHg in the outpatient setting

Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP/BIPAP used solely for sleep disordered breathing

Trial design

Treatments tested in this trial

  • Venovenous ECMO

Treatment groups

140 Participants
are divided into 2 treatment groups

Locations

7
Australia
St Vincent's Hospital Sydney2010, DarlinghurstNew South Wales, Australia
Royal Prince Alfred SydneyNew South Wales, Australia
The Prince Charles Hospital BrisbaneQueensland, Australia
Gold Coast University Hospital4217, Gold CoastQueensland, Australia

Sponsors and collaborators

Australian and New Zealand Intensive Care Research Centre

Lead sponsor

The Alfred

Collaborator